Expression of MK-1 and RegⅣ and its clinicopathological significances in the benign and malignant lesions of gallbladder

Diagnostic Pathology

Zhulin Yang²  Jieqiong Liu²  Sigen Lan²  Leping Yang¹ 

[1] Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA;Research laboratory of Hepatobiliary Diseases, Second Xiangya Hospital of Central South University, Changsha 410011,China

关键词: immunohistochemistry;    regenerating gene Ⅳ;    MK-1;    tumor-associated antigen;    chronic cholecystitis;    gallbladder polyp;    gallbladder neoplasms;   

Others  :  808221
DOI  :  10.1186/1746-1596-6-100

 received in 2011-06-27, accepted in 2011-10-21,  发布年份 2011

【 摘 要 】

Background

To study the expression of MK-1 and RegⅣ and to detect their pathological significances in benign and malignant lesions of gallbladder.

Methods

The expression of MK-1 and RegⅣ was detected by immunohistochemical method in paraffin-embedded sections of surgical resected specimens from gallbladder adenocarcinoma (n = 108), peritumoral tissues (n = 46), adenomatous polyp (n = 15), and chronic cholecystitis (n = 35).

Results

The positive rate of MK-1 or RegⅣ expression was significantly higher in gallbladder adenocarcinoma than that in peritumoral tissues (χ²_MK-1 = 18.76, P < 0.01; χ²_RegⅣ = 9.92, P < 0.01), denomatous polyp (χ²_MK-1 = 9.49, P < 0.01; χ²_RegⅣ = 8.59, P < 0.01) and chronic cholecystitis (χ²_MK-1 = 24.11, P < 0.01; χ²_RegⅣ = 19.24, P < 0.01). The positive cases of MK-1 and/or RegⅣ in the benign lesions showed moderately- or severe-atypical hyperplasia of gallbladder epitheli. The positive rates of MK-1 were significantly higher in the cases of well-differentiated adenocarcinoma, no-metastasis of lymph node, and no-invasiveness of regional tissues than those in the ones of differentiated adenocarcinoma, metastasis of lymph node, and invasiveness of regional tissues in gallbladder adenocarcinoma (P < 0.05 or P < 0.01). On the contrary, the positive rates of RegⅣ were significantly lower in the cases of well-differentiated adenocarcinoma, no-metastasis of lymph node, and no-invasiveness of regional tissues than those in the ones of differentiated adenocarcinoma, metastasis of lymph node, and invasiveness of regional tissues in gallbladder adenocarcinoma (P < 0.05 or P < 0.01). Univariate Kaplan-Meier analysis showed that decreased expression of MK-1 (P = 0.09) or increased expression of RegⅣ (P = 0.003) was associated with decreased overall survival. Multivariate Cox regression analysis showed that decreased expression of MK-1 (P = 0.033) and increased expression of RegⅣ (P = 0.008) was an independent prognostic predictor in gallbladder adenocarcinoma.

Conclusions

The expression of MK-1 and/or RegⅣ might be closely related to the carcinogenesis, clinical biological behaviors, and prognosis of gallbladder adenocarcinoma.

【 授权许可】

   
2011 Yang et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Abe H, Kuroki M, Imakiire T, Yamauchi Y, Yamada H, Arakawa F: Preparation of recombinant MK-1/Ep-CAM and establishment of an ELISA system for determining soluble MK-1/Ep-CAM levels in sera of cancer patients. J Immunol Methods 2002, 270(2):227-33.
• [2]Deveci MS, Deveci G: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer 2007, 10(2):112-6.
• [3]El-Meghawry El-Kenawy A, El-kott AF, Hamed SM, Kuroki M: Prognostic value of carcinoma-associated antigen MK-1 in urinary bladder carcinoma. Int J Biol Markers 2006, 21(3):170-4.
• [4]Ikeda T, Nakayama Y, Hamada Y, Takeshita M, Iwasaki H, Maeshiro K, Yamashita Y, Kuroki M, Ikeda S: FU-MK-1 expression in human gallbladder carcinoma: an antigenic prediction marker for a better postsurgical prognosis. American journal of clinical pathology 2009, 132(1):111-7.
• [5]Hamada Y, Nakayama Y, Mizoguchi M, Ikeda S, Kuroki M, Iwasaki H: MK-1 expression in carcinoma of the ampulla of Vater as a predictor of improved prognosis after surgical resection. Cancer letters 2006, 243(2):211-6.
• [6]Yamagishi H, Fukui H, Sekikawa A, Kono T, Fujii S, Ichikawa K, Tomita S, Imura J, Hiraishi H, Chiba T, Fujimori T: Expression profile of REG family proteins REG Ialpha and REG IV in advanced gastric cancer: comparison with mucin phenotype and prognostic markers. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2009, 22(7):906-13.
• [7]Kuniyasu H, Oue N, Sasahira T, Yi L, Moriwaka Y, Shimomoto T, Fujii K, Ohmori H, Yasui W: Reg IV enhances peritoneal metastasis in gastric carcinomas. Cell Prolif 2009, 42(1):110-21.
• [8]Bishnupuri KS, Luo Q, Korzenik JR, Henderson JO, Houchen CW, Anant S, Dieckgraefe BK: Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther 2006, 5(12):1714-20.
• [9]Pankova-Kholmyansky I, Arber N: Reg IV can serve for early diagnosis and therapy. Cancer Biol Ther 2007, 6(1):123-4.
• [10]Hayashi T, Matsubara A, Ohara S, Mita K, Hasegawa Y, Usui T, Arihiro K, Norimura S, Sentani K, Oue N, Yasui W: Immunohistochemical analysis of Reg IV in urogenital organs: Frequent expression of Reg IV in prostate cancer and potential utility as serum tumor marker. Oncol Rep 2009, 21(1):95-100.
• [11]Sasahira T, Oue N, Kirita T, Luo Y, Bhawal UK, Fujii K, Yasui W, Kuniyasu H: Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland. Histopathology 2008, 53(6):667-75.
• [12]Jayaraman S, Jarnagin WR: Management of gallbladder cancer. Gastroenterol Clin North Am 2010, 39(2):331-42. x
• [13]Leonardo E, Valente G, Cappia S, Cianfriglia M, Arancia G, Meschini S, Scagliotti GV: Immunohistochemical evaluation of P-glycoprotein in human malignancies by monoclonal antibody MC57. Int J Cancer 1994, 57(6):841-6.
• [14]Dowling GP, Kelly JK: The histogenesis of adenocarcinoma of the gallbladder. Cancer 1986, 58(8):1702-8.
• [15]Khalid H, Yasunaga A, Kishikawa M, Shibata S: Immunohistochemical expression of the estrogen receptor-related antigen (ER-D5) in human intracranial tumors. Cancer 1995, 75(10):2571-8.
• [16]Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H: Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci 2006, 97(11):1191-7.